Importance of combined-modality therapy for primary bone lymphoma

Leuk Lymphoma. 2003 Oct;44(10):1837-9. doi: 10.1080/1042819031000110937.

Abstract

Primary bone lymphoma (PBL) is a rare entity and comprises about 5% of all extranodal non-Hodgkin's lymphomas (NHL) and 7% of all primary bone tumors. To date there is no consensus about the optimal treatment for PBL. We retrospectively reviewed all cases of PBL treated at Hospital São Paulo, Brazil, over a 10-year-period (January 1992-January 2002). Medical records of 7 patients with PBL were reviewed and information on age at diagnosis, sex, NHL clinical staging (CS), treatment and response to treatment were retrieved. Five patients (72%) received combined-modality therapy (CMT) and all of them are in complete remission (CR) with a median follow up of 19 months (ranging from 12 to 144 months). We conclude that PBL is a potentially curable malignancy and treatment should be undertaken in a multiprofessional approach, in order to provide the best support which probably has to include chemotherapy, radiotherapy and, for patients with IPI higher than 2, consolidation with stem-cell transplantation.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Bone Neoplasms / complications
  • Bone Neoplasms / therapy*
  • Combined Modality Therapy
  • Female
  • Humans
  • Lymphoma, Non-Hodgkin / complications
  • Lymphoma, Non-Hodgkin / therapy*
  • Middle Aged
  • Remission Induction
  • Retrospective Studies